AntonsKAWilliamsCDBakerSKPhillipsPS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med2006;119:400–9.
2.
GrahamDJStaffaJAShatinDIncidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA2004;292:2585–90.
3.
WolfeSM. Dangers of rosuvastatin identified before and after FDA approval. Lancet2004;363:2189–90.
4.
McKenneyJMDavidsonMHJacobsonTAGuytonJR. Final conclusions and recommendations of the National Lipid Association Statin Assessment Safety Task Force. Am J Cardiol2006;97(Suppl):89C–94C.
5.
BrewerHBJr.Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol2003;92:23K–29K.
6.
McPhersonRFrohlichJFodorGGenestJ. Canadian Cardiovascular Society position statement — recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol2006;22:913–27.
7.
GrundySMCleemanJIMerzNBImplications of recent clinical trials for the National Cholesterol Education Treatment Program Adult Treatment Panel III guidelines. Circulation2004;110:227–39.
